The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Year: 2025
Type: article
Study design: Observational Study
Abstract: Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP (p < 0.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP (p < 0.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP (p = 0.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.
Source: Blood Cancer Journal
Authors: Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, Oren Pasvolsky, Mariola A. Vazquez-Martinez, Christopher J. Ferreri, Rahul Banerjee, Jack Khouri, James A. Davis, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma S. Rana, Kelley Julian, Faiz Anwer, Leyla Shune, Shaun DeJarnette, Ariel F. Grajales-Cruz, Evguenia Ouchveridze, Gabriel De Avila, Sandra P. Susanibar-Adaniya, Andrew J. Portuguese, Daniel Schrum, Erin Eberwein, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Joseph P. McGuirk, Adriana Rossi, Megan M. Herr, Omar Castaneda, Frederick L. Locke, Shahzad Raza, Yi Lin, Shebli Atrash, Douglas W. Sborov, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Surbhi Sidana, Krina K. Patel, Doris K. Hansen, Andrew J. Cowan, Larry D. Anderson, Hans C. Lee
Institutions: Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Fred Hutch Cancer Center, Thomas Jefferson University, Abramson Cancer Center, University of Pennsylvania, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Levine Cancer Institute, Wake Forest University, Medical University of South Carolina, Icahn School of Medicine at Mount Sinai, Stanford University, Huntsman Cancer Institute, University of Kansas, Duke University, Roswell Park Comprehensive Cancer Center, Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W4416780523